DOI: https://doi.org/10.15587/2519-4798.2017.91280

Визначення рівня β2-мікроглобуліну як прогностичного маркеру перебігу хронічної лімфоцитарної лейкемії

Ольга Ярославівна Виговська

Анотація


Проведено визначення рівня β2-мікроглобуліну (β2 МГ) у хворих на хронічну лімфоцитарну лейкемію (ХЛЛ) на різних стадіях хвороби. Встановлено, що рівень β2-МГ корелює зі стадією ХЛЛ, знаходиться в прямій залежності від об’єму пухлинної маси, є надійним прогностичним маркером відповіді на лікування у хворих на ХЛЛ. Рівень β2 МГ>3,5 мг/л в сироватці крові є поганим прогностичним провісником і свідчить про високий ризик хвороби


Ключові слова


хронічна лімфоцитарна лейкемія; β2 мікроглобулін; прогностичний маркер;стадія захворювання; лікування; виживання

Повний текст:

PDF

Посилання


Rai, K., Sawitsky, A., Cronkite, E., Chanana, A. D., Levy, R. N., Pasternack, B. S. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46 (2), 219–234.

Binet, J., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J. et. al. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48 (1), 198–206. doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v

Gribben, J. (2014). Prognostic and predictive factors in chronic lymphocytic leukemia. EHA Learning Center; Hematology Education, 8 (1), 59–74.

Shindiapina, P., Brown, J. R., Danilov, A. V. (2014). A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. British Journal of Haematology, 167 (2), 149–161. doi: 10.1111/bjh.13042

Truger, M. S., Jeromin, S., Weissmann, S., Dicker, F., Kern, W., Schnittger, S. et. al. (2014). Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia. British Journal of Haematology, 168 (1), 153–156. doi: 10.1111/bjh.13077

Binet, J.-L. (2005). Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood, 107 (3), 859–861. doi: 10.1182/blood-2005-04-1677

Tsimberidou, A., Tam, C., Wierda, W., Brien, S. O'., Lerner, S., Keating, M. J. (2007). Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl). Journal of Clinical Oncology, 25 (18), 7034.

Wierda, W. G., O’Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K.-A. et. al. (2007). Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood, 109 (11), 4679–4685. doi: 10.1182/blood-2005-12-051458

Güssow, D., Rein, R., Ginjaar, I., Hochstenbach, F., Seemann, G., Kottman, A. et. al. (1987). The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. The Journal of Immunology, 139 (9), 3132–3138.

Späti, B., Child, J. A., Kerruish, S. M., Cooper, E. H. (2009). Behaviour of Serum β2-Microglobulin and Acute Phase Reactant Proteins in Chronic Lymphocytic Leukaemia. Acta Haematologica, 64 (2), 79–86. doi: 10.1159/000207215

Di Giovanni, S., Valentini, G., Carducci, P., Giallonardo, P. (2009). Beta-2-Microglobulin Is a Reliable Tumor Marker in Chronic Lymphocytic Leukemia. Acta Haematologica, 81 (4), 181–185. doi: 10.1159/000205558

Hallek, M., Wanders, L., Ostwald, M., Busch, R., Senekowitsch, R., Stern, S. et. al. (1996). Serum β2-Microglobulin and Serum Thymidine Kinase are Independent Predictors of Progression-Free Survival in Chronic Lymphocytic Leukemia and Immunocytoma. Leukemia & Lymphoma, 22 (5-6), 439–447. doi: 10.3109/10428199609054782

Gentile, M., Cutrona, G., Neri, A., Molica, S., Ferrarini, M., Morabito, F. (2009). Predictive value of 2-microglobulin (2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica, 94 (6), 887–888. doi: 10.3324/haematol.2009.005561

Lai, R., O’Brien, S., Maushouri, T., Rogers, A., Kantarjian, H., Keating, M., Albitar, M. (2002). Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer, 95 (5), 1071–1075. doi: 10.1002/cncr.10772

Shanafelt, T. D. (2003). Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood, 103 (4), 1202–1210. doi: 10.1182/blood-2003-07-2281

Moreno, C., Montserrat, E. (2008). New prognostic markers in chronic lymphocytic leukemia. Blood Reviews, 22 (4), 211–219. doi: 10.1016/j.blre.2008.03.003

Delgado, J., Pratt, G., Phillips, N., Briones, J., Fegan, C., Nomdedeu, J. et. al. (2009). Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. British Journal of Haematology, 145 (6), 801–805. doi: 10.1111/j.1365-2141.2009.07699.x

Mozaheb, Z., NazarAbadi, M. H. H., Aghaee, M. A. (2012). Chronic Lymphocytic Leukemia and Prognostic Factors. Asian Pacific Journal of Cancer Prevention, 13 (7), 3009–3013. doi: 10.7314/apjcp.2012.13.7.3009

Shanafelt, T. D., Jenkins, G., Call, T. G., Zent, C. S., Slager, S., Bowen, D. A. et. al. (2008). Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer, 115 (2), 363–372. doi: 10.1002/cncr.24004

Hamblin, T., Davis, Z., Gardiner, A., Oscier, D. G., Stevenson, F. K. (1999). UnmutatedIg V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94 (6), 1848–1854.

Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L. et. al. (2000). Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 343 (26), 1910–1916. doi: 10.1056/nejm200012283432602

Del Principe, M. I., Bo, M. D., Bittolo, T., Buccisano, F., Rossi, F. M., Zucchetto, A. et. al. (2015). Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica, 101 (1), 77–85. doi: 10.3324/haematol.2015.131854

Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H. et. al. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111 (12), 5446–5456. doi: 10.1182/blood-2007-06-093906

Pflug, N., Bahlo, J., Shanafelt, T. D., Eichhorst, B. F., Bergmann, M. A., Elter, T. et. al. (2014). Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood, 124 (1), 49–62. doi: 10.1182/blood-2014-02-556399

Wierda, W. G., O’Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K.-A. et. al. (2011). Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 29 (31), 4088–4095. doi: 10.1200/jco.2010.33.9002

Tam, C. S., Seymour, J. F. (2014). A new prognostic score for CLL. Blood, 124 (1), 1–2. doi: 10.1182/blood-2014-05-575407

Kutsch, N., Bahlo, N., Byrd, J. et. al. (2015). The international Prognostic Index for patients with CLL (CLL-IPI): An international meta-analysis. Journal of Clinical Oncology, 33. Available at: http://meetinglibrary.asco.org/content/146941-156


Пристатейна бібліографія ГОСТ


Rai, K. Clinical staging of chronic lymphocytic leukemia [Text] / K. Rai, A. Sawitsky, E. Cronkite, A. D. Chanana, R. N. Levy, B. S. Pasternack // Blood. – 1975. – Vol. 46, Issue 2. – P. 219–234.

Binet, J. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis [Text] / J. Binet, A. Auquier, G. Dighiero, C. Chastang, H. Piguet, J. Goasguen et. al. // Cancer. – 1981. – Vol. 48, Issue 1. – P. 198–206. doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v

Gribben, J. Prognostic and predictive factors in chronic lymphocytic leukemia [Text] / J. Gribben // EHA Learning Center Hematology Education. – 2014. – Vol. 8, Issue 1. – P. 59–74.

Shindiapina, P. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53 [Text] / P. Shindiapina, J. Brown, A. Danilov // British Journal of Haematology. – 2014. – Vol. 167, Issue 2. – P. 149–161. doi: 10.1111/bjh.13042

Truger, M. Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia [Text] / M. Truger, S. Jeromin, S. Weissmann, F. Dicker, W. Kern, S. Schnittger et. al. // British Journal of Haematology. – 2014. – Vol. 168, Issue 1. – P. 153–156. doi: 10.1111/bjh.13077

Binet, J. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia [Text] / J. Binet // Blood. – 2006. – Vol. 107, Issue 3. – P. 859–861. doi: 10.1182/blood-2005-04-1677

Tsimberidou, A. Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) [Text] / A. Tsimberidou, C. Tam, W. Wierda, S. O'. Brien, S. Lerner, M. J. Keating // Journal of Clinical Oncology. – 2007. – Vol. 25, Issue 18. – P. 7034.

Wierda, W. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia [Text] / W. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do et. al. // Blood. – 2007. – Vol. 109, Issue 11. – P. 4679–4685. doi: 10.1182/blood-2005-12-051458

Güssow, D. The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit [Text] / D. Güssow, R. Rein, I. Ginjaar, F. Hochstenbach, G. Seemann, A. Kottman et. al. // The Journal of Immunology. – 1987. – Vol. 139, Issue 9. – P. 3132–3138.

Späti, B. Behaviour of serum beta 2-microglobulin and acute phase reactant proteins in chronic lymphocytic leukaemia. A multicentre study [Text] / B. Späti, J. Child, S. Kerruish, E. H. Cooper // Acta Haematologica. – 2009. – Vol. 64, Issue 2. – P. 79–86. doi: 10.1159/000207215

Di Giovanni, S. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia [Text] / S. Di Giovanni, G. Valentini, P. Carducci, P. Giallonardo // Acta haematologica. – 1989. – Vol. 81, Issue 4. – P. 181–185. doi: 10.1159/000205558

Hallek, M. Serum beta(2)- microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma [Text] / M. Hallek, L. Wanders, M. Ostwald, R. Busch, R. Senekowitsch, S. Stern et. al. // Leukemia & Lymphoma. – 1996. – Vol. 22, Issue 5-6. – P. 439–447. doi: 10.3109/10428199609054782

Gentile, M. Predictive value of 2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages [Text] / M. Gentile, G. Cutrona, A. Neri, S. Molica, M. Ferrarini, F. Morabito // Haematologica. – 2009. – Vol. 94, Issue 6. – P. 887–888. doi: 10.3324/haematol.2009.005561

Lai, R. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia [Text] / R. Lai, S. O’Brien, T. Maushouri, A. Rogers, H. Kantarjian, M. Keating, M. Albitar // Cancer. – 2002. – Vol. 95, Issue 5. – P. 1071–1075. doi: 10.1002/cncr.10772

Shanafelt, T. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL [Text] / T. Shanafelt // Blood. – 2003. – Vol. 103, Issue 4. – P. 1202–1210. doi: 10.1182/blood-2003-07-2281

Moreno, C. New prognostic markers in chronic lymphocytic leukemia [Text] / C. Moreno, E. Montserrat // Blood Reviews. – 2008. – Vol. 22, Issue 4. – P. 211–219. doi: 10.1016/j.blre.2008.03.003

Delgado, J. Beta 2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate [Text] / J. Delgado, G. Pratt, N. Phillips, J. Briones, C. Fegan, J. Nomdedeu et. al. // British Journal of Haematology. – 2009. – Vol. 145, Issue 6. – P. 801–805. doi: 10.1111/j.1365-2141.2009.07699.x

Mozaheb, Z. Chronic lymphocytic leukemia and prognostic factors [Text] / Z. Mozaheb, M. H. H. NazarAbadi, M. Aghaee et. al. // Asian Pacific Journal of Cancer Prevention. – 2012. – Vol. 13, Issue 7. – P. 3009–3013. doi: 10.7314/apjcp.2012.13.7.3009

Shanafelt, T. Validation of a new prognostic index for patients with chronic lymphocytic leukemia [Text] / T. Shanafelt, G. Jenkins, T. Call, C. S. Zent, S. Slager, D. A. Bowen et. al. // Cancer. – 2009. – Vol. 115, Issue 2. – P. 363–372. doi: 10.1002/cncr.24004

Hamblin, T. UnmutatedIg V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia [Text] / T. Hamblin, Z. Davis, A. Gardiner, D. G. Oscier, F. K. Stevenson // Blood. – 1999. – Vol. 94, Issue 6. – P. 1848–1854.

Dohner, H. Genomic aberrations and survival in chronic lymphocytic leukemia [Text] / H. Dohner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber, L. Bullinger et. al. // The New England Journal of Medicine. – 2000. – Vol. 343, Issue 26. – P. 1910–1916. doi: 10.1056/nejm200012283432602

Del Principe, M. Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia [Text] / M. Del Principe, M. Dal Bo, T. Bittolo, F. Buccisano, F. M. Rossi, A. Zucchetto et. al. // Haematologica. – 2015. – Vol. 101, Issue 1. – P. 77–85. doi: 10.3324/haematol.2015.131854

Hallek, M. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines [Text] / M. Hallek, B. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner et. al. // Blood. – 2008. – Vol. 111, Issue 12. – P. 5446–5456. doi: 10.1182/blood-2007-06-093906

Pflug, N. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia [Text] / N. Pflug, J. Bahlo, T. Shanafelt, B. F. Eichhorst, M. A. Bergmann, T. Elter et. al. // Blood. – 2014. – Vol. 124, Issue 1. – P. 49–62. doi: 10.1182/blood-2014-02-556399

Wierda, W. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia [Text] / W. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do et. al. // Journal of Clinical Oncology. – 2011. – Vol. 29, Issue 31. – P. 4088–4095. doi: 10.1200/jco.2010.33.9002

Tam, C. A new prognostic score for CLL [Text] / C. Tam, J. Seymour // Blood. – 2014. – Vol. 124, Issue 1. – P. 1–2. doi: 10.1182/blood-2014-05-575407

Kutsch, N. The international Prognostic Index for patients with CLL (CLL-IPI): An international meta-analysis [Text] / N. Kutsch, J. Bahlo, J. Byrd et. al. // Journal of Clinical Oncology. – 2015. – Vol. 33. – Available at: http://meetinglibrary.asco.org/content/146941-156







Copyright (c) 2017 Ольга Ярославівна Виговська

Creative Commons License
Ця робота ліцензована Creative Commons Attribution 4.0 International License.

ISSN 2519-4798 (Online), ISSN 2519-478X (Print)